Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2018 Apr 24;71(16):1755-1764.
doi: 10.1016/j.jacc.2018.02.037. Epub 2018 Mar 19.

Myocarditis in Patients Treated With Immune Checkpoint Inhibitors

Affiliations
Free PMC article
Multicenter Study

Myocarditis in Patients Treated With Immune Checkpoint Inhibitors

Syed S Mahmood et al. J Am Coll Cardiol. .
Free PMC article

Abstract

Background: Myocarditis is an uncommon, but potentially fatal, toxicity of immune checkpoint inhibitors (ICI). Myocarditis after ICI has not been well characterized.

Objectives: The authors sought to understand the presentation and clinical course of ICI-associated myocarditis.

Methods: After observation of sporadic ICI-associated myocarditis cases, the authors created a multicenter registry with 8 sites. From November 2013 to July 2017, there were 35 patients with ICI-associated myocarditis, who were compared to a random sample of 105 ICI-treated patients without myocarditis. Covariates of interest were extracted from medical records including the occurrence of major adverse cardiac events (MACE), defined as the composite of cardiovascular death, cardiogenic shock, cardiac arrest, and hemodynamically significant complete heart block.

Results: The prevalence of myocarditis was 1.14% with a median time of onset of 34 days after starting ICI (interquartile range: 21 to 75 days). Cases were 65 ± 13 years of age, 29% were female, and 54% had no other immune-related side effects. Relative to controls, combination ICI (34% vs. 2%; p < 0.001) and diabetes (34% vs. 13%; p = 0.01) were more common in cases. Over 102 days (interquartile range: 62 to 214 days) of median follow-up, 16 (46%) developed MACE; 38% of MACE occurred with normal ejection fraction. There was a 4-fold increased risk of MACE with troponin T of ≥1.5 ng/ml (hazard ratio: 4.0; 95% confidence interval: 1.5 to 10.9; p = 0.003). Steroids were administered in 89%, and lower steroids doses were associated with higher residual troponin and higher MACE rates.

Conclusions: Myocarditis after ICI therapy may be more common than appreciated, occurs early after starting treatment, has a malignant course, and responds to higher steroid doses.

Keywords: cardio-oncology; checkpoint inhibitor; ipilimumab; myocarditis; nivolumab; pembrolizumab.

Figures

FIGURE 1
FIGURE 1. Clinical Presentation of Patients With ICI-Associated Myocarditis
Time from ICI to onset of clinical myocarditis in each of the 35 cases of myocarditis (A). The ICI was administered on day 0. A description of the results for the ECG (B), troponin (C), LVEF (D), and natriuretic peptides (E), standard tests performed at the time of presentation with myocarditis, in patients with myocarditis related to ICI. ECG = electrocardiography; ICI = immune checkpoint inhibitors; LVEF = left ventricular ejection fraction; NT-proBNP = N-terminal pro–B-type natriuretic peptide.
CENTRAL ILLUSTRATION
CENTRAL ILLUSTRATION. Algorithm for Work-Up and Management of Immune-Mediated Myocarditis
Algorithm based on study findings, and institutional experience with 35 cases of ICI-associated myocarditis. CVD = cardiovascular; ECG = electrocardiogram; ICI = immune checkpoint inhibitors.

Comment in

Similar articles

  • Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors.
    Awadalla M, Golden DLA, Mahmood SS, Alvi RM, Mercaldo ND, Hassan MZO, Banerji D, Rokicki A, Mulligan C, Murphy SPT, Jones-O'Connor M, Cohen JV, Heinzerling LM, Armanious M, Sullivan RJ, Damrongwatanasuk R, Chen CL, Gupta D, Kirchberger MC, Moslehi JJ, Shah SP, Ganatra S, Thavendiranathan P, Rizvi MA, Sahni G, Lyon AR, Tocchetti CG, Mercurio V, Thuny F, Ederhy S, Mahmoudi M, Lawrence DP, Groarke JD, Nohria A, Fradley MG, Reynolds KL, Neilan TG. Awadalla M, et al. J Immunother Cancer. 2019 Feb 22;7(1):53. doi: 10.1186/s40425-019-0535-y. J Immunother Cancer. 2019. PMID: 30795818 Free PMC article.
  • Global Longitudinal Strain and Cardiac Events in Patients With Immune Checkpoint Inhibitor-Related Myocarditis.
    Awadalla M, Mahmood SS, Groarke JD, Hassan MZO, Nohria A, Rokicki A, Murphy SP, Mercaldo ND, Zhang L, Zlotoff DA, Reynolds KL, Alvi RM, Banerji D, Liu S, Heinzerling LM, Jones-O'Connor M, Bakar RB, Cohen JV, Kirchberger MC, Sullivan RJ, Gupta D, Mulligan CP, Shah SP, Ganatra S, Rizvi MA, Sahni G, Tocchetti CG, Lawrence DP, Mahmoudi M, Devereux RB, Forrestal BJ, Mandawat A, Lyon AR, Chen CL, Barac A, Hung J, Thavendiranathan P, Picard MH, Thuny F, Ederhy S, Fradley MG, Neilan TG. Awadalla M, et al. J Am Coll Cardiol. 2020 Feb 11;75(5):467-478. doi: 10.1016/j.jacc.2019.11.049. J Am Coll Cardiol. 2020. PMID: 32029128
  • Myocarditis in a patient treated with Nivolumab and PROSTVAC: a case report.
    Monge C, Maeng H, Brofferio A, Apolo AB, Sathya B, Arai AE, Gulley JL, Bilusic M. Monge C, et al. J Immunother Cancer. 2018 Dec 18;6(1):150. doi: 10.1186/s40425-018-0473-0. J Immunother Cancer. 2018. PMID: 30563577 Free PMC article.
  • Cardiovascular toxicities associated with immune checkpoint inhibitors.
    Hu JR, Florido R, Lipson EJ, Naidoo J, Ardehali R, Tocchetti CG, Lyon AR, Padera RF, Johnson DB, Moslehi J. Hu JR, et al. Cardiovasc Res. 2019 Apr 15;115(5):854-868. doi: 10.1093/cvr/cvz026. Cardiovasc Res. 2019. PMID: 30715219 Free PMC article. Review.
  • Cardiotoxicity from immune checkpoint inhibitors.
    Michel L, Rassaf T, Totzeck M. Michel L, et al. Int J Cardiol Heart Vasc. 2019 Sep 7;25:100420. doi: 10.1016/j.ijcha.2019.100420. eCollection 2019 Dec. Int J Cardiol Heart Vasc. 2019. PMID: 31517036 Free PMC article. Review.
See all similar articles

Cited by 102 articles

See all "Cited by" articles

Publication types

Feedback